Biocytogen
Donghui Yu is an experienced professional in the pharmaceutical industry with a focus on business development and preclinical research services. Currently serving as a Preclinical CRO Business Development Specialist at Medicilon USA Corp. and Associate Director of Business Development at Medicilon Inc., Donghui's expertise includes various aspects of pharmaceutical R&D outsourcing services. Previous roles include Business Development Manager at Biocytogen and Executive Director at VuRoyal Pharmaceutical Company and Oakmontscript LP, both of which specialize in FDA-approved pharmaceutical products for research and clinical use. Donghui began a scientific career as an Investigator at Novartis and a Scientist at Cubist Pharmaceuticals after earning a Ph.D. in Pharmacology from Peking University and a Bachelor's degree in Pharmacology from China Pharmaceutical University.
Biocytogen
2 followers
Biocytogen is a preclinical stage biotech that provides a one-stop solution for antibody discovery from target to IND application. With cutting-edge technologies, state-of-art animal facility, and world-class platforms for antibody drug discovery, Biocytogen offers animal model generation, antibody fully human-mouse (RenMab mouse), therapeutic antibody discovery and development, in vivo/in vitro preclinical studies, CMC/CDMO, and regulatory affairs support.